FDA expands Elevidys approval to include non-ambulatory Duchenne patients, then later restricts to ambulatory only

Sarepta Therapeutics/Elevidys

The FDA approved Elevidys for both ambulatory and non-ambulatory Duchenne patients 4 years and older, expanding access based on Phase 3 data. This approval was later revised in November 2025 when safety concerns emerged.